Skip to search formSkip to main contentSkip to account menu

MammaPrint

An in vitro molecular diagnostic test that uses gene expression profiling to analyze gene activity within a breast cancer tumor sample. It looks at… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Abstract P6-09-10: Results of multigene assay (MammaPrint®) and molecular subtyping (BluePrint®) substantially impact treatment decision making in early breast cancer: Final analysis of the WSG PRIME…
Background: In luminal early breast cancer (EBC) with limited nodal involvement, current guidelines recommend to use multigene… 
2017
2017
Abstract S2-06: DNA repair deficiency biomarkers and MammaPrint high1/(ultra)high2 risk as predictors of veliparib/carboplatin response: Results from the neoadjuvant I-SPY 2 trial for high risk…
Background: The PARP inhibitor veliparib in combination with carboplatin (VC) was one of the experimental regimens evaluated in… 
2016
2016
Abstract P5-07-04: Pathology data predicts MammaPrint result- The Magee MammaPrint equation
Introduction Prognosis for breast cancer patients may be determined using clinical-pathologic data (CPD) or gene expression… 
2016
2016
Abstract P5-08-06: Comparison of risk prediction with the 21-gene recurrence score (oncotype DX) and the 70-gene signature (MammaPrint) in patients with estrogen receptor-positive early stage breast…
Background: Gene expression profiling assays estimate prognosis & predict benefit from adjuvant chemotherapy in patients (pts… 
Review
2013
Review
2013
Abstract P6-06-02: Direct comparison of risk classification between MammaPrint®, Oncotype DX® and MammoStrat® assays in patients with early stage breast cancer
Several genomic tests for the prediction of breast cancer recurrence are commercially available and their clinical use is… 
2013
2013
Abstract P2-11-23: MammaPrint and BluePrint in early breast cancer: Clinical implications of prognostic stratification and molecular subtyping
Background: Combined use of MammaPrint and a molecular subtyping profile (BluePrint) identifies disease subgroups with marked… 
2012
2012
Abstract P6-07-03: Risk classification of Early Stage Breast Cancer as Assessed by MammaPrint and OncotypeDX Genomic Assays:
Background: The 21-gene Oncotype DX® Recurrence Score® assay has been validated for prediction of 10-year risk of distant… 
2010
2010
Gene signatures as predictors of response to neoadjuvant chemotherapy (NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and nab-paclitaxel (nab-P) and carboplatin {+/-} trastuzumab in…
540 Background: Pathologic complete response (pCR) and residual cancer burden (RCB) scores of 0 (pCR) and 1 (near CR) after NCT… 
2010
2010
Assays that predict outcomes make slow progress toward prime time.
A ssays that predict outcomes in chemotherapy or monitor the effects of treatment in real time, such as Oncotype DX and… 
2008
2008
Combined use of genomic prognostic and treatment response predictors in breast cancer
527 Background: An advantage of gene expression profiling-based diagnostic tests is that several different predictors can be… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)